Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | ANDROMEDA study: updated safety run-in results

Vaishali Sanchorawala • 15 Sep 2020
ISA 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone
ANDROMEDA

The Phase III ANDROMEDA (NCT03201965) study investigated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly-diagnosed light-chain (AL) amyloidosis. In this video, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the updated safety run-in results of the ANDROMEDA study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Vaishali Sanchorawala

1:55
Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis
Vaishali Sanchorawala • 11 Dec 2023
1:55
Quantifying biomarkers on lambda amyloidogenic light chains to diagnose AL amyloidosis
Vaishali Sanchorawala • 11 Dec 2023
1:58
Safety of birtamimab in AL amyloidosis: pooled analysis from multiple studies
Vaishali Sanchorawala • 12 Dec 2023
9:53
Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored
Ashutosh Wechalekar et al. • 9 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals